Etoposide-related acute promyelocytic leukemia.
The development of therapy-related acute myeloid leukemia (t-AML) has become a growing concern over the past decade, because of the increase in the percentage of long-term survivors of primary malignancy. We reviewed 17 cases with etoposide-related acute promyelocytic leukemia (APL) reported in the literature. The close association between treatment with etoposide for Langerhans cell histiocytosis (LCH) and the development of etoposide-related APL was demonstrated among Japanese and Italians. Our data on the breakpoints (b/ps) of the PML and RARalpha genes are presented. It is suggested that chromatin structure might be more important than specific consensus sequence in the distribution of b/ps in etoposide-related APL.
Kudo
K
K
Department of Pediatrics, Nagoya University School of Medicine, Japan.
Yoshida
H
H
Kiyoi
H
H
Numata
S
S
Horibe
K
K
Naoe
T
T
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001483:Base Sequence; D002648:Child; D002675:Child, Preschool; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D005047:Etoposide / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007223:Infant; D015473:Leukemia, Promyelocytic, Acute / Q000209:etiology* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000235:genetics*; D016609:Neoplasms, Second Primary / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D059005:Topoisomerase II Inhibitors
D000972:Antineoplastic Agents, Phytogenic; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D059005:Topoisomerase II Inhibitors; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D005047:Etoposide